Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Adenocarcinoma

Stomach Neoplasms

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Irinotecan

Topoisomerase I Inhibitors

Enzyme Inhibitors

Intraperitoneal Irinotecan given every three weeks

irinotecan

Syma Iqbal, M.D.

This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity.

Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan

University of Southern California

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Anti-Inflammatory Agents

Antirheumatic Agents

Analgesics

Celecoxib

Epothilone B

Epothilones

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase 2 Inhibitors

Cyclooxygenase Inhibitors

Tubulin Modulators

Antimitotic Agents

EPO906 IV, every three weeks, celecoxib by mouth twice a day every day

EPO906, celecoxib

Heinz-Josef Lenz, M.D.

This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA. EPO906 is a drug that has been shown in the laboratory to cause cancer cells to die and prevents them from growing and reproducing. Celebrex is a drug that is approved by the FDA for the treatment of arthritis and prevention of colon polyps. Colon polyps are small growths in the colon. If not surgically removed, some colon polyps can become cancerous. Some studies have shown that Celebrex may reduce the side effects of chemotherapy. Other studies have shown that it may increase the effectiveness of some chemotherapy. Celebrex is not approved by the FDA for reducing the side effects of chemotherapy or improving the effectiveness of chemotherapy. The combination of EPO906 and Celebrex in this study is experimental.

The main goal of this study is to see if adding the drug Celebrex to the drug EPO906 will decrease the amount of diarrhea seen in patients that receive EPO906.

The goal of the first phase of this study is to find the highest dose of EPO906 that can be given safely with Celebrex. The dose of Celebrex will remain the same for the whole study. Higher doses of EPO906 will be given to each group of patients. The increase of EPO906 will stop once more than one patient has serious side effects. The highest dose of EPO906 that can be given with Celebrex (without serious side effects) will be called the pilot dose.

The goal of the second phase of this study is to find out how tumors respond to these doses of the drugs. Another purpose of this study is to see how the body processes the EPO906 and Celebrex. This study will also look at the side effects of these drugs. In this study, we will measure how long subjects live, how often tumors shrink after receiving the study drugs, and how long it takes for tumors to increase in size after receiving the study drugs. This study will also measure the levels of genes, which are the cell's blueprint, in participant's tumors. Several genes can affect how people's bodies react to the cancer drugs. Genes will also be measured in participant's blood. We want to see if these predict response to the study drugs.

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)

Novartis

Anti-Infective Agents

Docetaxel

Doxorubicin

Liposomal doxorubicin

Anti-Bacterial Agents

Antibiotics, Antitubercular

liposomal doxorubicin and docetaxel

This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Colonic Neoplasms

Herbal and Botanical

Amino Acids

Capecitabine

Imatinib Mesylate

Antimetabolites

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Cola

Tyrosine

Capecitabine and imatinib mesylate will both be taken by mouth twice a day

capecitabine, imatinib mesylate

This study is for people with solid tumors cancer for which the standard chemotherapy drugs have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also called capecitabine) in combination with a new anticancer agent called Gleevec (also called imatinib mesylate). Xeloda is an anticancer drug, and can be taken by mouth. The active ingredient is a well-studied cancer drug called 5-FU. Xeloda is approved by the FDA for the treatment of colon cancer. Gleevec is approved in the US for the treatment of patients with a leukemia called CML (increase of white blood cells) after failure of standard therapy. It is also approved by the FDA for patients with Gastrointestinal Stromal Tumors (a rare tumor in the digestive tract).

This study will test how much Gleevec we can safely give with Xeloda. Xeloda will be given at the recommended dose for colorectal cancer and Gleevec will be given in increasing amounts.

Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan	NCT00183859	Adenocarcinoma Gastric Cancer	irinotecan	18 Years -	University of Southern California
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer	NCT00159484	Colon Cancer Colorectal Canc...	EPO906, celecox...	18 Years -	University of Southern California
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)	NCT00183742	Cancer Carcinoma	liposomal doxor...	18 Years -	University of Southern California
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors	NCT00183833	Colon Cancer Colorectal Canc...	capecitabine, i...	18 Years -	University of Southern California
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer	NCT00159484	Colon Cancer Colorectal Canc...	EPO906, celecox...	18 Years -	University of Southern California
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan	NCT00183859	Adenocarcinoma Gastric Cancer	irinotecan	18 Years -	University of Southern California
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors	NCT00183833	Colon Cancer Colorectal Canc...	capecitabine, i...	18 Years -	University of Southern California
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)	NCT00183742	Cancer Carcinoma	liposomal doxor...	18 Years -	University of Southern California

Spots Global Cancer Trial Database for phase one

Every month we try and update this database with for phase one cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for phase one

Every month we try and update this database with for phase one cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for phase one cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.